Patients with high NADM8 scores were older and exhibited a higher frequency of specific gene mutations in the ELN adverse risk group (e.g., TP53, SF3B1, ASXL1, U2AF1), which were reported to be enriched in elderly AML patients (41–43). Here, TP53 is linked to acute myeloid leukemia.